Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab
Henrik Horndalsveen, Nina Helbekkmo, Maria Moksnes Bjaanæs, Astrid Marie Dalsgaard et al.
Journal
Frontiers in Oncology
Topics
Lung Cancer Treatments and Mutations
article
Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab
Henrik Horndalsveen, Nina Helbekkmo, Maria Moksnes Bjaanæs, Astrid Marie Dalsgaard, Saulius Cicėnas, Tarje Onsøien Halvorsen, Jussi Pekka Koivunen, Åsa Kristina Öjlert, Kersti Oselin, Beate Danielsen, Daniel Nebdal, S.J. Farooqi, Tesfaye Madebo, Jarkko Ahvonen, Åslaug Helland, Maria Silvoniemi, Vilde Drageset Haakensen, Marianne Aanerud, Bjørn Henning Grønberg, Tonje Sofie Dalen, Mari Børve
article en
Abstract
No abstract available for this paper.
Publication Tag
Frontiers in OncologyVol. 15
Institutions
Oslo University Hospital (NO), University Hospital of North Norway (NO), Vilnius University (LT), University of Oslo (NO), Norwegian University of Science and Technology (NO), Oulu University Hospital (FI), Stavanger University Hospital (NO), Haukeland University Hospital (NO), Turku University Hospital (FI), North Estonia Medical Centre (EE), St Olav's University Hospital (NO), Tampere University Hospital (FI), Cancer Registry of Norway (NO), Tampere University (FI), National Cancer Institute (LT), University of Bergen (NO)